Table 1.

Indications and Dosing for FDA-Approved Asthma Biologies

DRUG	INDICATION	DOSING
OMALIZUMAB	Add-on maintenance treatment for moderate-to-severe persistent asthma in those aged 6 years or older with a positive skin test or in vitro reactivity to a perennial aeroallergen, and symptoms that are inadequately controlled with inhaled corticosteroids.	75 to 375 mg SC every 2 or 4 weeks*
MEPOLIZUMAB	Add-on maintenance treatment of patients with severe eosinophilic asthma, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).	100 mg SC every 4 weeks (bodyweight ≥ 40 kg); 40 mg SC every 4 weeks (bodyweight < 40 kg)
	Newly approved as an add-on maintenance treatment of patients with severe eosinophilic asthma aged 6 years or older.
RESLIZUMAB	Add-on maintenance treatment of patients with severe asthma, aged 18 years and older and with an eosinophilic phenotype.	3 mg/kg IV every 4 weeks
BENRALIZUMAB	Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.	30 mg SC every 4 weeks X 3 doses, then every 8 weeks
DUPILUMAB	Add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.	400 or 600* mg (two injections) SC followed by 200 or 300** mg every other week

^*Dose and frequency is determined by serum total IgE level (lU/mL) pre-treatment & body weight (kg).

^**300 mg (600 mg initial) dose is indicated for those with oral corticosteroid dependent asthma or with atopic dermatitis. Abbreviations: IV: intravenous, kg: kilogram, mg: milligram, SC: subcutaneous